DelveInsight’s “Bipolar Depression Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Bipolar Depression market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Bipolar Depression market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Bipolar Depression: An Overview
Bipolar disorder (BD) is a mental disorder characterized by mood swings between depression and mania. Based on the characteristic of the episodes, Bipolar Depression is majorly classified into BD-I, BD-II, cyclothymic disorder, and bipolar disorder not otherwise specified (NOS).
Many factors, such as genetic or hereditary changes, change in brain structure and function, environmental triggers, and psychological and social circumstances, are considered to cause Bipolar Depression. The diagnosis of bipolar depression is very challenging, and it is often misdiagnosed as unipolar depression. The diagnosis usually requires a physical examination, psychiatric assessment, mood charting, and the use of DSM-V criteria for bipolar episodes in Bipolar Depression.
The medications approved by the US FDA for bipolar depression include olanzapine‐fluoxetine combination (OFC), Quetiapine, Lurasidone as a monotherapy and as an adjunctive to ongoing lithium or valproate for bipolar I depression, and Cariprazine. For the refractory patient or first line for treating bipolar depression with psychotic features, electroconvulsive therapy is considered.
Bipolar Depression Market Key Facts
In the United States, the total diagnosed prevalent cases of Bipolar Depression treated cases in the 7MM were observed as 2,380K in the year 2021, these cases are estimated to increase in coming years.
In the year 2021, the type-specific cases of Bipolar Depression were 934K and 1445K cases for Bipolar Depression I and Bipolar Depression II, respectively, in the US.
In Japan, the severity-specific cases of Bipolar Depression were 5.6K, 30.9K, and 107.5K cases for mild, moderate, and severe, respectively, in the year 2021.
As per the DelveInsight estimates, in EU-5, the total treated cases of Bipolar Depression were 568.1K in the year 2021.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Bipolar Depression market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Bipolar Depression market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Bipolar Depression Market Drivers
Future Directions in Blood Biomarkers
Increase in Awareness and Technology
Advances Toward Precision Medicine for Bipolar Depression
Bipolar Depression Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Bipolar Depression Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bipolar Depression market or expected to get launched during the study period. The analysis covers the Bipolar Depression market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bipolar Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Bipolar Depression Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market
Bipolar Depression Therapeutics Analysis
The Bipolar Depression treatment space will experience significant growth due to the continuous effort by the companies actively engaged in research and development activities.
Some of the key companies in the Bipolar Depression Market include:
Sunovion (Sumitomo Dainippon Pharma)
Bipolar Depression Therapies Covered in the report include:
Caplyta (Lumateperone; ITI-007)
COMP 360 (Psilocybin Therapy)
Falkieri (Esketamine DPI)
And many more.
The pipeline for Bipolar Depression brings a positive ray of hope for a better treatment pattern in the market in the upcoming years. The current scenario also anticipates a positive shift in the market for the study period.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Bipolar Depression Competitive Intelligence Analysis
4. Bipolar Depression Market Overview at a Glance
5. Bipolar Depression Disease Background and Overview
6. Bipolar Depression Patient Journey
7. Bipolar Depression Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Bipolar Depression Treatment Algorithm, Current Treatment, and Medical Practices
9. Bipolar Depression Unmet Needs
10. Key Endpoints of Bipolar Depression Treatment
11. Bipolar Depression Marketed Products
12. Bipolar Depression Emerging Drugs and Latest Therapeutic Advances
13. Bipolar Depression Seven Major Market Analysis
14. Attribute Analysis
15. Bipolar Depression Market Outlook (In US, EU5, and Japan)
16. Bipolar Depression Access and Reimbursement Overview
17. KOL Views on the Bipolar Depression Market
18. Bipolar Depression Market Drivers
19. Bipolar Depression Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
DelveInsight’s “Bipolar Depression Pipeline Insights, 2022” report outlays comprehensive insights into the present clinical development scenario and growth prospects across the Bipolar Depression therapeutics market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States